News

Polymyositis Therapeutics Market Size in 7MM is expected to grow at a decent CAGR by 2034, estimates DelveInsight
DelveInsight’s “Polymyositis Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth ...
AFP2d
Merck Presents Positive Phase 2 Data for Enpatoran Demonstrating Reduction in Disease Activity in Patients with Cutaneous Lupus Erythematosus (CLE) and Systemic Lupus ...
Merck, a leading science and technology company, today announced positive data on enpatoran, an investigational, oral, novel TLR7/8 inhibitor, demonstrating clinically meaningful reduction in ...
rmdopen.bmj2d
Performance of the proposed ACR–EULAR classification criteria for systemic lupus erythematosus (SLE) in a cohort of patients with SLE with neuropsychiatric symptoms - RMD Open
Systemic lupus erythematosus (SLE) is a heterogenic connective tissue disease with a broad spectrum of clinical and laboratory manifestations. Due to this heterogeneity, SLE remains challenging to ...
Healio4d
‘Exciting to report’: Dapirolizumab bests placebo in achieving lupus low disease activity
Dapirolizumab pegol, a novel CD40L inhibitor, is superior to placebo for achieving low disease activity and remission in ...
CNX Software14d
$7 NearLink WS63E board supports Wi-Fi 6, BLE, and SparkLink Low Energy (SLE)
The HiHope_NearLink_DK_WS63E_V03 is a low-power NearLink dev board built around the HiHope HH-SPARK-WS63E module, which features the HiSilicon NearLink WS63E SoC with 2.4GHz Wi-Fi 6, BLE 5.2, and ...
Monash University18d
TRM-SLE project overview - The TRM-SLE project - Monash University
The TRM-SLE project explained. The Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE) project will develop a new clinical outcome assessment for SLE clinical trials that accurately ...
Monash University18d
TRM-SLE information for industry - The TRM-SLE project - Monash University
The TRM-SLE Taskforce is open to new industry partners. Contact us. To express interest in becoming a TRM-SLE industry partner or for any general enquiries related to the TRM-SLE project, please ...
BMJ19d
European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance - Annals of the Rheumatic Diseases
Background/objectives The European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) 2019 classification criteria for systemic lupus erythematosus system showed high specificity ...
The Lancet19d
Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 ...
In this post-hoc analysis, data were pooled from the randomised, placebo-controlled, phase 3 TULIP-1 (NCT02446912) and TULIP-2 (NCT02446899) trials of anifrolumab (300 mg intravenously once every 4 ...
BMJ19d
Prolonged remission in Caucasian patients with SLE: prevalence and outcomes
Aim To assess the prevalence of prolonged remission in Caucasian patients affected with systemic lupus erythematosus (SLE) and its relationship with damage accrual. Methods Caucasian patients ...
lupus.bmj20d
Associations of metabolic syndrome in SLE
Objectives To characterise the prevalence and associations of metabolic syndrome (MetS) in a multiethnic cohort of patients with SLE.Methods Using a standardised protocol, baseline demographics, per ...
Frontiers20d
Risk, risk factors, and screening of malignancies in dermatomyositis: current status and future perspectives - Frontiers
Polymyositis-dermatomyositis and Malignant lesions: does an association exist? Mayo Clin Proc. (1986) 61:645–53. doi: 10.1016/s0025-6196(12)62030-8. PubMed Abstract | Crossref Full Text | Google ...